# A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis

> **NCT06084988** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cellcolabs Clinical SPV Limited** · enrollment: 12 (actual)

## Conditions studied

- Osteo Arthritis Knee

## Interventions

- **BIOLOGICAL:** Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)

## Key facts

- **NCT ID:** NCT06084988
- **Lead sponsor:** Cellcolabs Clinical SPV Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-07
- **Primary completion:** 2024-10-29
- **Final completion:** 2024-10-29
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084988, "A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06084988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*